Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 2 | 2 |
| 1.1 List of Tables | 3 | 1 |
| 1.2 List of Figures | 3 | 1 |
| 2 Introduction | 3 | 3 |
| 2.1 What Is This Report About? | 4 | 1 |
| 2.2 Magnetic Resonance Imaging (MRI) Systems Market Segmentation | 4 | 1 |
| 2.3 Definitions of Markets Covered in the Report | 5 | 1 |
| 3 MRI Systems Market, Mexico | 6 | 13 |
| 3.1 MRI Systems Market, Mexico, Revenue ($m), 2008-2015 | 6 | 2 |
| 3.2 MRI Systems Market, Mexico, Revenue ($m), 2015-2022 | 8 | 2 |
| 3.3 MRI Systems Market, Mexico, Volume (Units), 2008-2015 | 10 | 2 |
| 3.4 MRI Systems Market, Mexico, Volume (Units), 2015-2022 | 12 | 2 |
| 3.5 MRI Systems Market, Mexico, Average Price ($), 2008-2022 | 14 | 2 |
| 3.6 MRI Systems Market, Mexico, Distribution Share by Revenue ($m), 2014-2015 | 16 | 1 |
| 3.7 MRI Systems Market, Mexico, Company Share by Revenue ($m), 2015 | 17 | 2 |
| 4 Overview of Key Companies in Mexico, MRI Systems Market | 19 | 2 |
| 4.1 Siemens Limited | 19 | 1 |
| 4.1.1 Company Overview | 19 | 1 |
| 4.2 GE Healthcare Limited | 19 | 1 |
| 4.2.1 Company Overview | 19 | 1 |
| 4.3 Philips Healthcare | 19 | 1 |
| 4.3.1 Company Overview | 19 | 1 |
| 4.4 Toshiba Medical Systems Corporation | 20 | 1 |
| 4.4.1 Company Overview | 20 | 1 |
| 5 MRI Systems Market Pipeline Products | 21 | 2 |
| 6 Financial Deals Landscape | 23 | 3 |
| 6.1 Partnerships | 23 | 1 |
| 6.1.1 MagnetTx Oncology Solutions Enters into Licensing Agreement with Alberta Health Services and University of Alberta | 23 | 2 |
| 6.1.2 Terumo Enters into Distribution Agreement with Quirem Medical | 25 | 1 |
| 7 Appendix | 26 | 7 |
| 7.1 Research Methodology | 27 | 5 |
| 7.1.1 Coverage | 27 | 1 |
| 7.1.2 Secondary Research | 27 | 1 |
| 7.1.3 Primary Research | 28 | 1 |
| 7.1.4 Market Modeling and Forecasting | 29 | 1 |
| 7.1.5 Company Share Analysis | 30 | 1 |
| 7.1.6 Distribution Share Analysis | 31 | 1 |
| 7.1.7 Benchmarking | 31 | 1 |
| 7.2 GlobalData Consulting | 31 | 1 |
| 7.3 Contact Us | 32 | 1 |
| 7.4 Disclaimer | 32 | 1 |
